Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740042 | 1.00 | TDP1 (0.68) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL5888624 | 1.00 | TDP1 (0.68) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL5610837 | 0.98 | TDP1 (0.70) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL30058168 | 0.98 | TDP1 (0.70) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL825505 | 0.93 | TDP1 (0.72) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL352046 | 0.91 | TDP1 (0.81) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL9814241 | 0.91 | TDP1 (0.81) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL2331250 | 0.91 | TDP1 (0.81) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL353009 | 0.91 | TDP1 (0.81) | TDP1SMN1; SMN2LMNATSHRALOX15 | |
| SCHEMBL3161153 | 0.89 | TDP1 (0.84) | TDP1SMN1; SMN2LMNATSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445533-B2 | Andrographolide derivatives to treat viral infections | CORNELL RESEARCH FOUNDATION, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-1817024-A2 | ANDROGRAPHOLIDE DERIVATIVES TO TREAT VIRAL INFECTIONS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060223785-A1 | Andrographolide derivatives to treat viral infections | CORNELL RESEARCH FOUNDATION, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006101538-A2 | ANDROGRAPHOLIDE DERIVATIVES TO TREAT VIRAL INFECTIONS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | EMORY UNIVERSITY | 2002-09-12 | — | — | US | disclosed |
| WO-2002047679-A2 | NONPEPTIDE AGONISTS AND ANTAGONISTS OF VASOPRESSIN RECEPTORS | EMORY UNIVERSITY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-5684029-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-11-04 | — | — | US | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5587393-A | ANGIOTENSIN ANTAGONIST USEFUL IN TREATING HYPERTENSION | DR. KARL THOMAE GMBH (DE) | 1996-12-24 | — | — | US | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| US-5385925-A | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223785-A1 | Andrographolide derivatives to treat viral infections | HAVCR2, MAVS, EIF2AK2 | TDP1 2239/4885SMN1; SMN2 3651/4885LMNA 2482/4885 |
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | AVPR1A, AVPR2, AVPR1B | TDP1 3328/4885SMN1; SMN2 4469/4885LMNA 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.